Liver Biology and Pathobiology

You have full text access to this OnlineOpen article

TRAIL-mediated apoptosis requires NF-kB inhibition and the mitochondrial permeability transition in human hepatoma cells

  1. Young-Soo Kim1,2,
  2. Robert F. Schwabe1,2,
  3. Ting Qian3,
  4. John J. Lemasters3,
  5. David A. Brenner1,2,*

Article first published online: 7 MAR 2007

DOI: 10.1002/hep.1840360627

Issue

Hepatology

Hepatology

Volume 36, Issue 6, pages 1498–1508, December 2002

Additional Information

How to Cite

Kim, Y.-S., Schwabe, R. F., Qian, T., Lemasters, J. J. and Brenner, D. A. (2002), TRAIL-mediated apoptosis requires NF-kB inhibition and the mitochondrial permeability transition in human hepatoma cells. Hepatology, 36: 1498–1508. doi: 10.1002/hep.1840360627

Author Information

  1. 1

    Department of Medicine, University of North Carolina, Chapel Hill, NC

  2. 2

    Department of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC

  3. 3

    Department of Cell and Developmental Biology, University of North Carolina, Chapel Hill, NC

*Department of Medicine, CB 7038, 156 Glaxo, University of North Carolina, Chapel Hill, NC 27599. fax: 919–966–7468

Publication History

  1. Issue published online: 7 MAR 2007
  2. Article first published online: 7 MAR 2007
  3. Manuscript Accepted: 4 SEP 2002
  4. Manuscript Received: 12 JUL 2002

Funded by

  • NIH. Grant Numbers: DK 34987, GM41804, DK 59340

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (1189K)

Reference

  • 1
    Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673–682.
  • 2
    Havell EA, Fiers W, North RJ. The antitumor function of tumor necrosis factor (TNF) I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. J Exp Med 1988; 167: 1067–1085.
  • 3
    Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993; 364: 806–809.
  • 4
    Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, et al. Tumoricidal activity of tumor necrosis factor-related apoptosisinducing ligand in vivo. Nat Med 1999; 5: 157–163.
  • 5
    Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155–162.
  • 6
    Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271: 12687–12690.
  • 7
    Gores GJ, Kaufmann SH. Is TRAIL hepatotoxic? Hepatology 2001; 34: 3–6.
    Direct Link:
  • 8
    Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997; 277: 815–818.
  • 9
    Degli-Esposti MA, Smolak PJ, Walczak H, Waugh J, Huang CP, DuBose RF, Goodwin RG, et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997; 186: 1165–1170.
  • 10
    Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. The novel receptor TRAIL-R4 induces NF-kB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997; 7: 813–820.
  • 11
    Griffith TS, Rauch CT, Smolak PJ, Waugh JY, Boiani N, Lynch DH, Smith CA, et al. Functional analysis of TRAIL receptors using monoclonal antibodies. J Immunol 1999; 162: 2597–2605.
  • 12
    Holler N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti S, Bodmer JL, et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol 2000; 1: 489–495.
  • 13
    Suliman A, Lam A, Datta R, Srivastava RK. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways. Oncogene 2001; 20: 2122–2133.
  • 14
    Jeremias I, Kupatt C, Baumann B, Herr I, Wirth T, Debatin KM. Inhibition of nuclear factor-kB activation attenuates apoptosis resistance in lymphoid cells. Blood 1998; 91: 4624–4631.
  • 15
    Franco AV, Zhang XD, Van Berkel E, Sanders JE, Zhang XY, Thomas WD, Nguyen T, et al. The role of NF-kB in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells. J Immunol 2001; 166: 5337–5345.
  • 16
    Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388: 190–195.
  • 17
    Mitsiades N, Mitsiades CS, Poulaki V, Anderson KC, Treon SP. Intracellular regulation of tumor necrosis factor-related apoptosis- inducing ligand-induced apoptosis in human multiple myeloma cells. Blood 2002; 99: 2162–2171.
  • 18
    Xiao C, Yang BF, Asadi N, Beguinot F, Hao C. TRAIL-induced death-inducing signaling complex (DISC) and its modulation by c-FLIP and PED/PEA-15 in glioma cells. J Biol Chem 2002; 25: 25.
  • 19
    Schneider P, Thome M, Burns K, Bodmer JL, Hofmann K, Kataoka T, Holler N, et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kB. Immunity 1997; 7: 831–836.
  • 20
    Hu WH, Johnson H, Shu HB. Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-kB and JNK activation and apoptosis through distinct pathways. J Biol Chem 1999; 274: 30603–30610.
  • 21
    Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-kB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c- IAP2 to suppress caspase-8 activation. Science 1998; 281: 1680–1683.
  • 22
    Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 1999; 59: 2747–2753.
  • 23
    Hinz S, Trauzold A, Boenicke L, Sandberg C, Beckmann S, Bayer E, Walczak H, et al. Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene 2000; 19: 5477–5486.
  • 24
    Burns TF, El-Deiry WS. Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach. J Biol Chem 2001; 276: 37879–37886.
  • 25
    Iimuro Y, Nishiura T, Hellerbrand C, Behrns KE, Schoonhoven R, Grisham JW, Brenner DA. NFkB prevents apoptosis and liver dysfunction during liver regeneration [published erratum appears in J Clin Invest 1998; 101: 1541]. J Clin Invest 1998; 101: 802–811.
  • 26
    Bradham CA, Qian T, Streetz K, Trautwein C, Brenner DA, Lemasters JJ. The mitochondrial permeability transition is required for tumor necrosis factor α-mediated apoptosis and cytochrome c release. Mol Cell Biol 1998; 18: 6353–6364.
  • 27
    Hatano E, Bradham CA, Stark A, Iimuro Y, Lemasters JJ, Brenner DA. The mitochondrial permeability transition augments Fas-induced apoptosis in mouse hepatocytes. J Biol Chem 2000; 275: 11814–11823.
  • 28
    Jobin C, Holt L, Bradham CA, Streetz K, Brenner DA, Sartor RB. TNF receptor-associated factor-2 is involved in both IL-1 β and TNF-α signaling cascades leading to NF-kB activation and IL-8 expression in human intestinal epithelial cells. J Immunol 1999; 162: 4447–4454.
  • 29
    Schwabe RF, Bennet BL, Manning AM, Brenner DA. Differential function of IkB kinase 1 and 2 in primary rat hepatocytes. Hepatology 2001; 33: 81–90.
    Direct Link:
  • 30
    Sakurai H, Chiba H, Miyoshi H, Sugita T, Toriumi W. IkB kinases phosphorylate NF-kB p65 subunit on serine 536 in the transactivation domain. J Biol Chem 1999; 274: 30353–30356.
  • 31
    Schwabe RF, Schnabl B, Kweon YO, Brenner DA. CD40 activates NF-kB and c-Jun N-terminal kinase and enhances chemokine secretion on activated human hepatic stellate cells. J Immunol 2001; 166: 6812–6819.
  • 32
    Nieminen AL, Gores GJ, Bond JM, Imberti R, Herman B, Lemasters JJ. A novel cytotoxicity screening assay using a multiwell fluorescence scanner. Toxicol Appl Pharmacol 1992; 115: 147–155.
  • 33
    Lemasters JJ, Trollinger DR, Qian T, Cascio WE, Ohata H. Confocal Imaging of Ca2+, pH, Electrical Potential, and Membrane Permeability in Single Living Cells. Volume 302. New York: Academic Press, 1999.
  • 34
    Nieminen AL, Saylor AK, Tesfai SA, Herman B, Lemasters JJ. Contribution of the mitochondrial permeability transition to lethal injury after exposure of hepatocytes to t-butylhydroperoxide. Biochem J 1995; 307: 99–106.
  • 35
    Yamanaka T, Shiraki K, Sugimoto K, Ito T, Fujikawa K, Ito M, Takase K, et al. Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. Hepatology 2000; 32: 482–490.
    Direct Link:
  • 36
    Kreuz S, Siegmund D, Scheurich P, Wajant H. NF-kB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol Cell Biol 2001; 21: 3964–3973.
  • 37
    Panka DJ, Mano T, Suhara T, Walsh K, Mier JW. Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells. J Biol Chem 2001; 276: 6893–6896.
  • 38
    Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y, Kraft AS. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 2001; 276: 10767–10774.
  • 39
    Lin Y, Devin A, Cook A, Keane MM, Kelliher M, Lipkowitz S, Liu ZG. The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkB kinase and c-Jun N-terminal kinase. Mol Cell Biol 2000; 20: 6638–6645.
  • 40
    Madrid LV, Mayo MW, Reuther JY, Baldwin AS Jr. Akt stimulates the transactivation potential of the RelA/p65 Subunit of NF-kB through utilization of the IkB kinase and activation of the mitogen-activated protein kinase p38. J Biol Chem 2001; 276: 18934–18940.
  • 41
    Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med 2000; 6: 513–519.
  • 42
    Thomas WD, Zhang XD, Franco AV, Nguyen T, Hersey P. TNF-related apoptosis-inducing ligand-induced apoptosis of melanoma is associated with changes in mitochondrial membrane potential and perinuclear clustering of mitochondria. J Immunol 2000; 165: 5612–5620.
Get PDF (1189K)